People · Operator
Named in public records as an officer, director or promoter · active 2010–2010 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Otonomy, Inc. | — | Biotechnology | Series B | $44.8M | $961.1M | 2010 |
Carl LeBel, Ph.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Carl LeBel, Ph.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jeffrey Harris | 1 | 9 |
| Peter Bisgaard | 1 | 9 |
| David Weber | 1 | 8 |
| Jay Lichter | 1 | 7 |
| Brian Dovey | 1 | 7 |
| Court Turner | 1 | 6 |
| John McKearn | 1 | 6 |
| Douglas Downs | 1 | 6 |
| Heather Preston | 1 | 6 |
| Jay Lichter, Ph.D. | 1 | 5 |
| Jeffrey Harris, M.D., Ph.D. | 1 | 1 |
| Gerald Wroblewski | 1 | 1 |
| Carl LeBel | 1 | 1 |
| Paul Cayer | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.